Sionna Therapeutics, Inc. beat EPS estimates 33% of the time across 3 reported quarters (1 beats, 2 misses), averaging +2.0% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.64 | $-0.66 | -3.1% | Miss | |
| Q1 FY26 | $-0.52 | $-0.60 | -15.4% | Miss | |
| Q4 FY25 | $-0.61 | $-0.46 | +24.6% | Beat |
Back to SION overview · SION holders · SION KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.